Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases

Key Points TNF inhibitors are among the most effective protein-based drugs for reducing inflammation associated with several rheumatic diseases In addition to TNF, the TNF superfamily (TNFSF) comprises other ligand–receptor combinations that might participate in the pathogenesis of rheumatic disease...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Nature reviews. Rheumatology Ročník 13; číslo 4; s. 217 - 233
Hlavní autoři:	Croft, Michael, Siegel, Richard M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 01.04.2017 Nature Publishing Group
Témata:	4-1BB Ligand - antagonists & inhibitors 4-1BB Ligand - metabolism 692/4023/1670 692/420/256 692/420/2780 692/700/565/1436 Animals Antigens Arthritis Care and treatment CD27 Ligand - antagonists & inhibitors CD27 Ligand - metabolism CD40 Ligand - antagonists & inhibitors CD40 Ligand - metabolism Cell Death Cytokine TWEAK Cytokines Dendritic cells Dendritic Cells - immunology Development and progression Fas Ligand Protein - antagonists & inhibitors Fas Ligand Protein - metabolism Genetic aspects Growth factors Health aspects Humans Immune system Immune Tolerance Ligands Lupus Lymphocyte Activation Lymphotoxin-alpha - antagonists & inhibitors Lymphotoxin-alpha - metabolism Medicine & Public Health Molecular Targeted Therapy OX40 Ligand - antagonists & inhibitors OX40 Ligand - metabolism Proteins review-article Rheumatic diseases Rheumatic Diseases - drug therapy Rheumatic Diseases - immunology Rheumatology Signal Transduction T-Lymphocytes - immunology TNF-Related Apoptosis-Inducing Ligand - antagonists & inhibitors TNF-Related Apoptosis-Inducing Ligand - metabolism Tumor necrosis factor Tumor Necrosis Factor Ligand Superfamily Member 14 - antagonists & inhibitors Tumor Necrosis Factor Ligand Superfamily Member 14 - metabolism Tumor Necrosis Factor Ligand Superfamily Member 15 - antagonists & inhibitors Tumor Necrosis Factor Ligand Superfamily Member 15 - metabolism Tumor Necrosis Factors - antagonists & inhibitors Tumor Necrosis Factors - immunology Tumor Necrosis Factors - metabolism La Jolla California United States > US
ISSN:	1759-4790, 1759-4804
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Key Points TNF inhibitors are among the most effective protein-based drugs for reducing inflammation associated with several rheumatic diseases In addition to TNF, the TNF superfamily (TNFSF) comprises other ligand–receptor combinations that might participate in the pathogenesis of rheumatic disease TNFSF members initiate several processes, including immune activation, tissue inflammatory responses and cell death or suppression Many TNFSF proteins other than TNF are being evaluated in preclinical mouse or human studies as possible therapeutic targets in rheumatic diseases TNFSF members can be targeted to either restore tolerance in rheumatic diseases or to regulate tissue cell responses In this Review, the authors discuss the function of the TNF and TNF receptor superfamily, their role in rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, and how current knowledge is being translated into potential disease therapies. TNF blockers are highly efficacious at dampening inflammation and reducing symptoms in rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and also in nonrheumatic syndromes such as inflammatory bowel disease. As TNF belongs to a superfamily of 19 structurally related proteins that have both proinflammatory and anti-inflammatory activity, reagents that disrupt the interaction between proinflammatory TNF family cytokines and their receptors, or agonize the anti-inflammatory receptors, are being considered for the treatment of rheumatic diseases. Biologic agents that block B cell activating factor (BAFF) and receptor activator of nuclear factor-κB ligand (RANKL) have been approved for the treatment of systemic lupus erythematosus and osteoporosis, respectively. In this Review, we focus on additional members of the TNF superfamily that could be relevant for the pathogenesis of rheumatic disease, including those that can strongly promote activity of immune cells or increase activity of tissue cells, as well as those that promote death pathways and might limit inflammation. We examine preclinical mouse and human data linking these molecules to the control of damage in the joints, muscle, bone or other tissues, and discuss their potential as targets for future therapy of rheumatic diseases.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1759-4790 1759-4804
DOI:	10.1038/nrrheum.2017.22